IGC logo

IGC
IGC Pharma Inc

30,170
Mkt Cap
$28.05M
Volume
550.00
52W High
$0.4985
52W Low
$0.2525
PE Ratio
-3.88
IGC Fundamentals
Price
$0.302
Prev Close
$0.306
Open
$0.305
50D MA
$0.3786
Beta
0.58
Avg. Volume
639,630.84
EPS (Annual)
-$0.0931
P/B
3.43
Rev/Employee
$18,157.14
Loading...
Loading...
News
all
press releases
IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates
IGC Pharma, Inc. (IGC) delivered earnings and revenue surprises of 0.00% and -56.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·20d ago
News Placeholder
More News
News Placeholder
Profound Medical (PROF) Reports Q3 Loss, Tops Revenue Estimates
Profound Medical (PROF) delivered earnings and revenue surprises of +31.58% and +0.74%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·21d ago
News Placeholder
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of +43.48% and -77.27%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·22d ago
News Placeholder
Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of +233.33% and +2.08%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·24d ago
News Placeholder
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -77.78% and +4.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·28d ago
News Placeholder
All You Need to Know About IGC Pharma, Inc. (IGC) Rating Upgrade to Strong Buy
IGC Pharma, Inc. (IGC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·1mo ago
News Placeholder
Best Momentum Stocks to Buy for Oct. 24
ASM, IGC and RY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 24, 2025.
Zacks·1mo ago
News Placeholder
New Strong Buy Stocks for Oct. 24: IGC, ASM and More
IGC, SCRYY, RY, UVE and ASM have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 24, 2025.
Zacks·1mo ago
News Placeholder
IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates
IGC Pharma, Inc. (IGC) delivered earnings and revenue surprises of +33.33% and -0.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Hyperfine, Inc. (HYPR) Reports Q2 Loss, Lags Revenue Estimates
Hyperfine (HYPR) delivered earnings and revenue surprises of 0.00% and -7.03%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago

Latest IGC News

View

Advertisement|Remove ads.

Advertisement|Remove ads.